Loading...
The treatment of multidrug-resistant tuberculosis is hampered by a paucity of therapeutic agents and by toxicity of antimicrobials, particularly aminoglycosides. Minocycline is active against Mycobacterium tuberculosis (MTB), so recently approved antibiotics derived from minocycline may offer more-potent therapy. Tigecycline is a minocycline derivative designed to subvert tetracycline efflux pumps and ribosomal protection mechanisms of resistance and demonstrates favorable pulmonary pharmacokinetics. Building on prior work probing for compounds with activity against MTB, investigators have now examined tigecycline efficacy in vitro.
The median tigecycline minimum inhibitory concentration (MIC) of 30 MTB strains was 2 mg/L. In a hollow-fiber …